Traditional Chinese medicine composition for treating ischemic stroke and preparation method and application thereof

Abstract

The invention relates to a traditional Chinese medicine composition for treating ischemic stroke and a method and application thereof, and belongs to the technical field of traditional Chinese medicines. The invention discloses a traditional Chinese medicine composition for treating ischemic stroke. The traditional Chinese medicine composition is prepared from the following raw materials: ginseng, pseudo-ginseng, radix polygoni multiflori preparata, ligusticum wallichii, safflower carthamus, salvia miltiorrhiza, hawthorn, loranthus parasiticus, longspur epimedium, radix puerariae, cornu bubali, ginseng leaves, rhizoma acori graminei and borneol. According to the preparation method disclosed by the invention, the ligusticum wallichii and compound bacteria consisting of lactobacillus plantarum, bacillus subtilis and coriolus hirsutus are fermented, so that more laccase and active substances are generated in a fermented product, and then the fermented product is subjected to compound enzyme treatment, so that the processed ligusticum wallichii is better in medicine effect, and the curative effect of the ligusticum wallichii is improved. Therefore, the treatment effect of the traditional Chinese medicine composition for treating ischemic stroke is enhanced, neurological dysfunction caused by cerebral ischemia can be remarkably relieved, and the traditional Chinese medicine composition has a good protection effect on ischemic stroke nerve injury.

Description

Technical Field

[0001] The invention belongs to the technical field of traditional Chinese medicines, and relates to a traditional Chinese medicine composition for treating ischemic stroke, and a preparation method and application thereof. Background Art

[0002] Chuanxiong is known as "blood qi medicine", which can regulate the body's blood circulation and improve the body's internal environment. Chuanxiong can improve the body's blood circulation by anticoagulation, antithrombosis, increasing blood volume, vasodilation and lowering blood pressure, regulating the body's glucose and lipid metabolism, etc. Its active substances are mainly divided into: volatile oils, alkaloids, polysaccharides, organic acids, etc. The level of active content plays a very important role in the effect of efficacy. Different extraction methods will also affect the type and content of chemical components, and the pharmacodynamic properties are different. At present, there are steam distillation, supercritical CO2 extraction, etc. These methods are not ideal for the extraction of active ingredients of Chuanxiong. Therefore, the Chinese medicine composition for treating ischemic stroke provided by the present invention and its preparation method and application can effectively improve the extraction of active ingredients of Chuanxiong. Summary of the invention

[0003] The present invention relates to a Chinese medicine composition for treating ischemic stroke, and a preparation method and application thereof, and belongs to the technical field of Chinese medicine. The Chinese medicine composition for treating ischemic stroke disclosed in the present invention comprises the following raw materials in parts by weight: 2-4 parts of ginseng, 5-7 parts of notoginseng, 40-50 parts of processed polygonum multiflorum, 10-20 parts of chuanxiong, 10-15 parts of safflower, 30-50 parts of salvia miltiorrhiza, 25-30 parts of hawthorn, 25-30 parts of mistletoe, 26-30 parts of epimedium, 35-40 parts of kudzu root, 70-90 parts of buffalo horn, 15-25 parts of ginseng leaf, 10-15 parts of calamus, and 1-3 parts of borneol. In the present invention, the composite bacteria consisting of Chuanxiong, Lactobacillus plantarum, Bacillus subtilis and Pseudomonas aeruginosa are fermented to produce more laccase and active substances in the fermented product, and the fermented product is then treated with the composite enzyme, so that the Chuanxiong obtained by the treatment has better medicinal effect, thereby enhancing the blood circulation and analgesic effects of the traditional Chinese medicine composition, reducing the effect of neurological dysfunction caused by cerebral ischemia, and having a good protective effect on ischemic stroke nerve damage.

[0004] The purpose of the present invention can be achieved through the following technical solutions:

[0005] A Chinese medicine composition for treating ischemic stroke, comprising the following raw materials in parts by weight: 2-4 parts of ginseng, 5-7 parts of Panax notoginseng, 40-50 parts of processed Polygonum multiflorum, 10-20 parts of Chuanxiong, 10-15 parts of safflower, 30-50 parts of Salvia miltiorrhiza, 25-30 parts of hawthorn, 25-30 parts of mistletoe, 26-30 parts of epimedium, 35-40 parts of Pueraria root, 70-90 parts of buffalo horn, 15-25 parts of ginseng leaves, 10-15 parts of Acorus calamus, and 1-3 parts of borneol. The processing method of Chuanxiong comprises the following steps:

[0006] A1 ： Grind the rhizome of Chuanxiong, sieve to form powder, add distilled water to mix, heat to sterilize, and cool to form a mixture;

[0007] A2: adding composite bacteria to the mixture for mixed fermentation, adding composite enzymes to mix and then performing enzymolysis after the fermentation is completed, heating to inactivate the enzyme after the enzymolysis is completed, filtering to obtain filtrate a and filter residue, adding distilled water to the filter residue and heating, then filtering to obtain filtrate b, combining filtrate a and filtrate b, and concentrating under reduced pressure to form an extract, and completing the treatment steps after drying;

[0008] Wherein, the composite bacteria is composed of Pseudomonas aeruginosa, Bacillus subtilis and Lactobacillus plantarum;

[0009] The complex enzyme consists of cellulase and phospholipase.

[0010] Furthermore, the mesh size of the sieving in step A1 is 100-300 mesh, and the mass ratio of the powder to distilled water is 10-13:200-250.

[0011] Furthermore, in the step A1, the temperature and time of the heating sterilization are 120-150°C and 20-30min respectively, and the cooling temperature is 25-35°C.

[0012] Furthermore, in step A2, the ratio of the mixture to the composite bacteria is 1-3L:0.05-0.08g, the mass ratio of Lactobacillus plantarum, Bacillus subtilis and Pseudomonas aeruginosa is 1-2:1-1.5:1, and the temperature and time of the mixed fermentation are 30-38°C and 24-48h, respectively.

[0013] Furthermore, in step A2, the added amount of the composite enzyme is 3-5wt% of the total mass of the system, the mass ratio of the cellulase to the phospholipase is 1:1, and the enzymolysis conditions are: temperature of 40-60°C and time of 50-70min.

[0014] Furthermore, in step A2, the temperature is raised to 120° C. to perform enzyme inactivation treatment.

[0015] Furthermore, in step A2, the volume ratio of the filter residue to distilled water is 1:1-2, the heating temperature is 80-100°C, the pressure of the reduced pressure concentration is -0.06 to -0.08 MPa, and the temperature is 60°C.

[0016] Use of a Chinese medicine composition for treating ischemic stroke in preparing a medicine for treating ischemic stroke, wherein the medicine is a capsule. Beneficial effects of the invention:

[0017] The composite bacteria formed by the three bacteria of the burr fungus, the lactobacillus plantarum and the bacillus subtilis are used to ferment the chuanxiong. The burr fungus can produce laccase, and the lactobacillus plantarum and the bacillus subtilis can synergistically promote the growth of the burr fungus, so that the activity of the laccase in the fermentation product is significantly enhanced; the laccase is conducive to the degradation of the compounds in the chuanxiong, and the substances produced in the degradation process can be better used as a nutrient source for the growth of microorganisms. In addition, the mixed action of the fermentation product and the composite enzyme composed of cellulase and phospholipase makes the chuanxiong obtained by the treatment more effective, thereby enhancing the therapeutic effect of the Chinese medicine composition for treating ischemic stroke, which can significantly reduce the neurological dysfunction caused by cerebral ischemia and has a good protective effect on the neurological damage caused by ischemic stroke. DETAILED DESCRIPTION

[0018] In order to further illustrate the technical means and effects adopted by the present invention to achieve the predetermined invention purpose, the specific implementation methods, structures, features and effects of the present invention are described in detail below in combination with embodiments.

[0019] The experimental methods in the following examples without specifying specific conditions are usually carried out under conventional conditions or conditions recommended by the manufacturers. The materials and reagents used can be obtained from commercial sources unless otherwise specified.

[0020] The preservation number of the bursaphelenchus scaly is CCTCC No.M2021731, the preservation number of Bacillus subtilis is CGMCC No.1.15792, and the preservation number of Lactobacillus plantarum is CGMCC No.1.12974; and the effective viable counts of Bacillus subtilis and Lactobacillus plantarum are both 1*10 6 CFU / mL.

[0021] Cellulase was purchased from Hebei Tuohai Biotechnology Co., Ltd.;

[0022] Phospholipase was purchased from Chongqing Tianrun Biological Products Co., Ltd.;

[0023] SD rats: purchased from the Animal Experiment Center of Southern Medical University, production experimental animal license number: SCXK (Guangdong) 2021-0041; the experiment was conducted in the Animal Laboratory of the College of Veterinary Medicine of South China Agricultural University.

[0024] Example 1

[0025] A Chinese medicine composition for treating ischemic stroke, comprising the following raw materials in parts by weight: 2 parts of ginseng, 5 parts of Panax notoginseng, 40 parts of processed Polygonum multiflorum, 10 parts of Chuanxiong, 10 parts of safflower, 30 parts of Salvia miltiorrhiza, 25 parts of hawthorn, 25 parts of mistletoe, 26 parts of epimedium, 35 parts of Pueraria root, 70 parts of buffalo horn, 15 parts of ginseng leaves, 10 parts of Acorus calamus, and 1 part of borneol. The processing method of Chuanxiong comprises the following steps:

[0026] A1 ： Grind the rhizome of Chuanxiong, sieve to form powder, add distilled water to mix, heat to sterilize, and cool to form a mixture;

[0027] A2: adding composite bacteria to the mixture for mixed fermentation, adding composite enzymes to mix and then performing enzymolysis after the fermentation is completed, heating to inactivate the enzyme after the enzymolysis is completed, filtering to obtain filtrate a and filter residue, adding distilled water to the filter residue and heating, then filtering to obtain filtrate b, combining filtrate a and filtrate b, and concentrating under reduced pressure to form an extract, and completing the treatment steps after drying;

[0028] Wherein, the composite bacteria is composed of Pseudomonas aeruginosa, Bacillus subtilis and Lactobacillus plantarum;

[0029] The deposit number of Pseudomonas aeruginosa is CCTCC No.M2021731, the deposit number of Bacillus subtilis is CGMCC No.1.15792, and the deposit number of Lactobacillus plantarum is CGMCC No.1.12974;

[0030] The complex enzyme consists of cellulase and phospholipase.

[0031] The mesh number of the sieving in the step A1 is 100 mesh, and the mass ratio of the powder to distilled water is 10:200.

[0032] The temperature and time of the heating sterilization in step A1 are 120° C. and 20 min respectively, and the cooling temperature is 25° C.

[0033] The ratio of the mixture to the composite bacteria in step A2 is 1L:0.05g, the mass ratio of Lactobacillus plantarum, Bacillus subtilis and Pseudomonas aeruginosa is 1:1:1, and the temperature and time of the mixed fermentation are 30°C and 24h, respectively.

[0034] The added amount of the composite enzyme in step A2 is 3wt% of the total mass of the system, the mass ratio of the cellulase and the phospholipase is 1:1, the enzymolysis temperature is 40°C, and the enzymolysis time is 50min.

[0035] In step A2, the temperature is raised to 120°C for enzyme inactivation. In step A2, the volume ratio of the filter residue to distilled water is 1:1, the heating temperature is 80°C, and the pressure of the reduced pressure concentration is -0.06Mpa and the temperature is 60°C.

[0036] The drying in step A2 is freeze-drying.

[0037] Example 2

[0038] A Chinese medicine composition for treating ischemic stroke, comprising the following raw materials in parts by weight: 3 parts of ginseng, 6 parts of Panax notoginseng, 45 parts of processed Polygonum multiflorum, 15 parts of Chuanxiong, 13 parts of safflower, 40 parts of Salvia miltiorrhiza, 28 parts of hawthorn, 28 parts of mistletoe, 28 parts of epimedium, 38 parts of Pueraria root, 80 parts of buffalo horn, 20 parts of ginseng leaves, 13 parts of Acorus calamus, and 2 parts of borneol. The processing method of Chuanxiong comprises the following steps:

[0039] A1 ： Grind the rhizome of Chuanxiong, sieve to form powder, add distilled water to mix, heat to sterilize, and cool to form a mixture;

[0040] A2: adding composite bacteria to the mixture for mixed fermentation, adding composite enzymes to mix and then performing enzymolysis after the fermentation is completed, heating to inactivate the enzyme after the enzymolysis is completed, filtering to obtain filtrate a and filter residue, adding distilled water to the filter residue and heating, then filtering to obtain filtrate b, combining filtrate a and filtrate b, and concentrating under reduced pressure to form an extract, and completing the treatment steps after drying;

[0041] Wherein, the composite bacteria is composed of Pseudomonas aeruginosa, Bacillus subtilis and Lactobacillus plantarum;

[0042] The deposit number of Pseudomonas aeruginosa is CCTCC No.M2021731, the deposit number of Bacillus subtilis is CGMCC No.1.15792, and the deposit number of Lactobacillus plantarum is CGMCC No.1.12974;

[0043] The complex enzyme consists of cellulase and phospholipase.

[0044] The mesh number of the sieving in step A1 is 200 mesh, and the mass ratio of the powder to distilled water is 12:225.

[0045] The temperature and time for heating and sterilizing in step A1 are 135° C. and 25 min respectively, and the cooling temperature is 30° C.

[0046] The ratio of the mixture to the composite bacteria in step A2 is 2L:0.06g, the mass ratio of Lactobacillus plantarum, Bacillus subtilis and Pseudomonas aeruginosa is 1.5:1.3:1, and the temperature and time of the mixed fermentation are 34°C and 34h respectively.

[0047] The added amount of the composite enzyme in step A2 is 4wt% of the total mass of the system, the mass ratio of the cellulase and the phospholipase is 1:1, and the enzymolysis conditions are: temperature of 50°C and time of 60min.

[0048] In the step A2, the temperature is raised to 120° C. to perform enzyme inactivation treatment.

[0049] In the step A2, the volume ratio of the filter residue to the distilled water is 1:1.5, the heating temperature is 90° C., the pressure of the reduced pressure concentration is -0.07 MPa, and the temperature is 60° C.

[0050] The drying in step A2 is freeze-drying.

[0051] Example 3

[0052] A Chinese medicine composition for treating ischemic stroke, comprising the following raw materials in parts by weight: 4 parts of ginseng, 7 parts of Panax notoginseng, 50 parts of processed Polygonum multiflorum, 20 parts of Chuanxiong, 15 parts of safflower, 50 parts of Salvia miltiorrhiza, 30 parts of hawthorn, 30 parts of mistletoe, 30 parts of epimedium, 40 parts of Pueraria root, 90 parts of buffalo horn, 25 parts of ginseng leaves, 15 parts of Acorus calamus, and 3 parts of borneol. The processing method of Chuanxiong comprises the following steps:

[0053] A1: Grind the rhizome of Chuanxiong, sieve to form a powder, then add distilled water to mix, heat to sterilize, and cool to form a mixture;

[0054] A2: adding composite bacteria to the mixture for mixed fermentation, adding composite enzymes to mix and then performing enzymolysis after the fermentation is completed, heating to inactivate the enzyme after the enzymolysis is completed, filtering to obtain filtrate a and filter residue, adding distilled water to the filter residue and heating, then filtering to obtain filtrate b, combining filtrate a and filtrate b, and concentrating under reduced pressure to form an extract, and completing the treatment steps after drying;

[0055] Wherein, the composite bacteria is composed of Pseudomonas aeruginosa, Bacillus subtilis and Lactobacillus plantarum;

[0056] The deposit number of Pseudomonas aeruginosa is CCTCC No.M2021731, the deposit number of Bacillus subtilis is CGMCC No.1.15792, and the deposit number of Lactobacillus plantarum is CGMCC No.1.12974;

[0057] The complex enzyme consists of cellulase and phospholipase.

[0058] The mesh number of the sieving in step A1 is 300 meshes, and the mass ratio of the powder to distilled water is 13:250.

[0059] The temperature and time of the heating sterilization in step A1 are 150° C. and 30 min respectively, and the cooling temperature is 35° C.

[0060] The ratio of the mixture to the composite bacteria in step A2 is 3L:0.08g, the mass ratio of Lactobacillus plantarum, Bacillus subtilis and Pseudomonas aeruginosa is 2:1.5:1, and the temperature and time of the mixed fermentation are 38°C and 48h, respectively.

[0061] The added amount of the composite enzyme in step A2 is 5wt% of the total mass of the system, the mass ratio of the cellulase and the phospholipase is 1:1, and the enzymolysis conditions are: temperature is 60°C and time is 70min.

[0062] In step A2, the temperature is raised to 120° C. to perform enzyme inactivation treatment.

[0063] In the step A2, the volume ratio of the filter residue to the distilled water is 1:2, the heating temperature is 100° C., the pressure of the reduced pressure concentration is -0.08 MPa, and the temperature is 60° C.

[0064] The drying in step A2 is freeze-drying.

[0065] Comparative Example 1

[0066] Compared with Example 2, the only difference is that the composite bacteria in Comparative Example 1 does not contain Lactobacillus plantarum, and its reduced mass is proportionally distributed to the masses of Bacillus subtilis and Pseudomonas aeruginosa. Other conditions are consistent with Example 2.

[0067] Comparative Example 2

[0068] Compared with Example 2, the only difference is that the composite bacteria in Comparative Example 2 does not contain Bacillus subtilis, and its reduced mass is proportionally distributed to the masses of Lactobacillus plantarum and Pseudomonas aeruginosa, and other conditions are consistent with Example 2.

[0069] Comparative Example 3

[0070] Compared with Example 2, the only difference is that the mass ratio of Pseudomonas aeruginosa, Lactobacillus plantarum and Bacillus subtilis is 3:2:1, and other conditions are consistent with Example 2.

[0071] Comparative Example 4

[0072] Compared with Example 2, the only difference is that the mass ratio of Pseudomonas aeruginosa, Lactobacillus plantarum and Bacillus subtilis is 0.5:0.5:1, and other conditions are consistent with Example 2.

[0073] Comparative Example 5

[0074] Compared with Example 2, the only difference is that the Bacillus subtilis with a preservation number of CGMCC No. 1.12939 is used to replace the Bacillus subtilis with a preservation number of CGMCC No. 1.15792, and the other conditions are the same as those in Example 2.

[0075] Comparative Example 6

[0076] Based on Example 2, the only difference is that Lactobacillus plantarum with a preservation number of CGMCC No. 1.12935 is used to replace Lactobacillus plantarum with a preservation number of CGMCC No. 1.12974, and other conditions are consistent with Example 2.

[0077] Performance Testing

[0078] 1) Determination of laccase: ABTS method was used for determination

[0079] The fermented liquid in step A2 of Example 1-3 and Comparative Example 1-6 was used as a sample, and 5 times the volume of distilled water was added to the sample, and the mixture was heated at 4°C and 3000 r·min -1 Centrifuge for 20 minutes and take the supernatant. Take 2.9 ml of 0.5 mmol / L ABTS solution into a 1 cm cuvette and quickly transfer to a 30°C water bath to preheat for 5 minutes. Take 0.1 ml of the supernatant diluted 6000 times to start the reaction. Measure the absorbance (OD value) change within 4 minutes at a wavelength of 420 nm and record the △OD value. The amount of enzyme required to oxidize 1 μmol ABTS per minute is one enzyme activity unit. The laccase (Lac) activity is calculated according to the following formula: Lac = (△OD × n × 1 ml × 10 6 μmol / mol)÷(0.1ml×4min×ε), where the extinction coefficient ε=3.6×10 4 M -1 cm -1 , n is the dilution multiple of the enzyme solution, and the test results are shown in Table 1.

[0080] Table 1 Test results

[0081] Sample Laccase (Lac) activity / U Example 1 7500 Example 2 7800 Example 3 7600 Comparative Example 1 4600 Comparative Example 2 4300 Comparative Example 3 5600 Comparative Example 4 5400 Comparative Example 5 6800 Comparative Example 6 6700

[0082] From the data in Table 1, it can be seen that the laccase activity of Examples 1-3 is much greater than that of Comparative Examples 1-6. In Comparative Examples 1-2, Lactobacillus plantarum or Bacillus subtilis is missing respectively, and it can be seen that the laccase activity in the fermentation broth is significantly reduced compared with that in Examples 1-3; in Comparative Examples 3-4, the ratio of the use of Pseudomonas aeruginosa, Lactobacillus plantarum and Bacillus subtilis is adjusted, and the results show that the laccase activity is also reduced to a certain extent compared with the examples; the experimental data of Comparative Examples 5-6 show that the replacement of different strains of Bacillus subtilis and Lactobacillus plantarum will also affect the laccase activity in the fermentation broth.

[0083] 2) Animal experiment: 110 healthy male SPF SD rats were selected, weighing 250±50g, and the feeding conditions were: room temperature between 22 and 24°C, humidity between 40 and 70%, alternating light and dark lighting time of 12h, and free drinking water and food. Referring to the animal experiment in patent CN111700947A, the specific method is: SD rats were randomly divided into a sham operation group (normal group), a cerebral ischemia reperfusion group (model group) and 9 drug groups, 10 rats in each group, and before use, the Chinese medicine composition was obtained according to the corresponding method of the embodiment and the comparative example, and then the suspension was prepared with physiological saline. The drug group was gavaged with the corresponding drug suspension, and the sham operation group and the model group were gavaged with an equal amount of physiological saline, and the drug was gavaged once in the morning and evening every day. The neurobehavioral scores of rats in each group were measured 24h after gavage, and the cerebral infarction volume ratio was measured 72h after gavage. The specific method is as follows:

[0084] Treatment of cerebral ischemia-reperfusion model: The middle cerebral artery occlusion (MCAO) model was prepared according to the modified suture method of Longa et al.: Rats were anesthetized with sodium pentobarbital, fixed in the supine position, and disinfected with alcohol. A midline incision of about 1 cm was made in the neck, and blunt separation was performed to expose the right common carotid artery (CCA), external carotid artery (ECA), and internal carotid artery (ICA). The ECA was ligated, and the CCA was temporarily blocked with a thin line. The distal end of the ICA was temporarily clamped with a micro-arteriolar clamp. A "V" cut was made in the ECA near the bifurcation. A fishing line with a length of about 40 mm and a head diameter of 0.4 mm was inserted from the cut, from the ECA to the ICA, and gently pushed forward along the direction of the ICA. Do not mistakenly enter the pterygopalatine artery. The fishing line entered about 19 mm and stopped advancing when it encountered resistance. The fishing line was fixed on the ECA. After 90 minutes of ischemia, the suture line was pulled out to achieve reperfusion, and the ECA was ligated near the bifurcation. The incision was sutured and disinfected with alcohol to prevent infection. No fishing line was inserted in the sham operation group. Other experimental steps were the same as above.

[0085] Neurological function score: Rats were graded according to the 0-3 points grading method of Bederson et al., and the symptoms of neurological deficit were observed and recorded 24 hours after modeling: no neurological deficit was grade 0; flexion of the limbs on the opposite side of the lesion when the tail was lifted was grade 1; in addition to the grade 1 signs, there was a decrease in the resistance to lateral push to the opposite side of the lesion, which was grade 2; in addition to the grade 1 and grade 2 signs, there was a sign of rotation to the paralyzed side during activity, which was grade 3. Rats that died during surgery or were found to have skull base hemorrhage after death were excluded;

[0086] Cerebral infarction volume ratio: After the experimental rats were gavaged and given the drug, their heads were cut off and the brains were quickly placed in a refrigerator at -20°C for 10 minutes. When the brains reached a certain hardness, they were taken out and 6 coronal slices were cut along the ruler from the frontal pole of the forebrain with a sharp blade. Each slice was 2.5 mm thick. The brain slices were placed in 2% TTC staining solution and incubated at 37°C for 30 minutes. The brain slices were fixed in a freshly prepared 10% formaldehyde solution. The brain slices were arranged in the order of the slices, and the photos were taken with a digital camera and entered into the computer. The ischemic area of ​​each slice and the overall area were calculated using the image analysis method, and then the infarction area ratio was calculated.

[0087] The experimental data were analyzed by variance analysis using SPSS statistical software, and P < 0.05 indicated that the difference was statistically significant.

[0088] The experimental results are shown in Table 2.

[0089] Table 2 Effect of neurobehavioral scores and cerebral infarction volume ratio in rats

[0090] Group Rating impact / 24h Infarct volume ratio Model Group 2.62±0.25 0.284±0.038 Sham operation group 0.22±0.28 0 Example 1 <![CDATA[1.56±0.55 ＊ ]]> <![CDATA[0.048±0.035 ＊＊ ]]> Example 2 <![CDATA[1.42±0.63 ＊ ]]> <![CDATA[0.046±0.036 ＊＊ ]]> Example 3 <![CDATA[1.58±0.54 ＊ ]]> <![CDATA[0.050±0.041 ＊＊ ]]> Comparative Example 1 2.35±0.84 0.234±0.054 Comparative Example 2 2.28±0.71 0.236±0.062 Comparative Example 3 2.15±0.51 0.219±0.075 Comparative Example 4 2.18±0.69 0.217±0.052 Comparative Example 5 1.98±0.75 <![CDATA[0.164±0.032 ＊ ]]> Comparative Example 6 1.89±0.87 <![CDATA[0.166±0.042 ＊ ]]>

[0091] Note: “*” represents P<0.05, “**” represents P<0.01, compared with the model group.

[0092] It can be concluded from Table 2 that compared with the model group, the neurological function scores of Examples 1-3 have significant differences, indicating that the Chinese medicine composition of the present invention can significantly reduce the symptoms of neurological deficits in rats (P<0.05), and the cerebral infarction volume ratio compared with the model group also has extremely significant differences (P<0.01). In addition, compared with the experimental data of other comparative examples, the embodiments show that the present invention uses a composite bacteria formed by a specific ratio of burr fungus, plant lactobacillus, and Bacillus subtilis to ferment Chuanxiong, and the three are fermented together and then treated with enzymes, and the Chuanxiong obtained by the treatment has better efficacy, thereby enhancing the therapeutic effect of the Chinese medicine composition for treating ischemic stroke, can reduce the neurological dysfunction caused by transient cerebral ischemia in rats, can significantly reduce the volume of cerebral infarction in rats, and has a good protective effect on ischemic stroke nerve damage.

[0093] The above description is only a preferred embodiment of the present invention and does not limit the present invention in any form. Although the present invention has been disclosed as a preferred embodiment as above, it is not used to limit the present invention. Any technical personnel in this field can make some changes or modify the technical contents disclosed above into equivalent embodiments without departing from the scope of the technical solution of the present invention. However, any brief modifications, equivalent changes and modifications made to the above embodiments based on the technical essence of the present invention without departing from the content of the technical solution of the present invention are still within the scope of the technical solution of the present invention.

Claims

1. A Chinese medicine composition for treating ischemic stroke, characterized in that: The Chinese medicine composition for treating ischemic stroke comprises the following raw materials in parts by weight: 2-4 parts of ginseng, 5-7 parts of Panax notoginseng, 40-50 parts of processed Polygonum multiflorum, 10-20 parts of Chuanxiong, 10-15 parts of safflower, 30-50 parts of Salvia miltiorrhiza, 25-30 parts of hawthorn, 25-30 parts of mistletoe, 26-30 parts of epimedium, 35-40 parts of Pueraria root, 70-90 parts of buffalo horn, 15-25 parts of ginseng leaves, 10-15 parts of Acorus calamus, and 1-3 parts of borneol. The method for processing Chuanxiong comprises the following steps: A1 ： Grind the rhizome of Chuanxiong, sieve to form powder, add distilled water to mix, heat to sterilize, and cool to form a mixture; A2: adding composite bacteria to the mixture for mixed fermentation, adding composite enzymes to mix and then performing enzymolysis after the fermentation is completed, heating to inactivate the enzyme after the enzymolysis is completed, filtering to obtain filtrate a and filter residue, adding distilled water to the filter residue and heating, then filtering to obtain filtrate b, combining filtrate a and filtrate b, and concentrating under reduced pressure to form an extract, and completing the treatment steps after drying; Wherein, the composite bacteria is composed of Pseudomonas aeruginosa, Bacillus subtilis and Lactobacillus plantarum; The complex enzyme consists of cellulase and phospholipase.

2. A Chinese medicine composition for treating ischemic stroke according to claim 1, characterized in that: The mesh size of the sieving in step A1 is 100-300 meshes, and the mass ratio of the powder to distilled water is 10-13:200-250.

3. A Chinese medicine composition for treating ischemic stroke according to claim 1, characterized in that: The temperature and time of the heating sterilization in step A1 are 120-150°C and 20-30 minutes respectively, and the cooling temperature is 25-35°C.

4. A Chinese medicine composition for treating ischemic stroke according to claim 1, characterized in that: The ratio of the mixture to the composite bacteria in step A2 is 1-3L:0.05-0.08g, the mass ratio of Lactobacillus plantarum, Bacillus subtilis and Pseudomonas aeruginosa is 1-2:1-1.5:1, and the temperature and time of the mixed fermentation are 30-38°C and 24-48h, respectively.

5. A Chinese medicine composition for treating ischemic stroke according to claim 1, characterized in that: The added amount of the composite enzyme in step A2 is 3-5wt% of the total mass of the system, the mass ratio of the cellulase and the phospholipase is 1:1, and the enzymolysis conditions are: temperature 40-60°C, time 50-70min.

6. A Chinese medicine composition for treating ischemic stroke according to claim 1, characterized in that: In the step A2, the temperature is raised to 120° C. to perform enzyme inactivation treatment.

7. A Chinese medicine composition for treating ischemic stroke according to claim 1, characterized in that: In the step A2, the volume ratio of the filter residue to the distilled water is 1:1-2, the heating temperature is 80-100°C; the pressure of the reduced pressure concentration is -0.06 to -0.08 MPa, and the temperature is 60°C.

8. Use of the Chinese medicine composition for treating ischemic stroke as claimed in any one of claims 1 to 7 in preparing a medicine for treating ischemic stroke, characterized in that: The medicine is a capsule.